Search

everythinglearnresearchcommunity

for

Search:↓

The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.

PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.

The user is experiencing hair loss and is using treatments like finasteride, minoxidil, and hormone replacement therapy (estradiol enanthate injections) to address it. They are advised to be patient with the treatments and consider using a dermapen for microneedling.

The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

A user is experiencing hair loss in the center of their hairline and has been using topical finasteride for seven months with minimal progress. They are considering switching treatments due to concerns about losing ground and potential side effects of other options.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

The conversation is about the potential effectiveness of a hair loss treatment called pyrilutamide. One person has been using it since September and reports positive results.

A 28-year-old underwent three hair transplants totaling 11,102 grafts at Eugenix, using finasteride and minoxidil to manage advanced hair loss. Despite limited density, the results are satisfactory, allowing the individual to feel presentable without a hat.

Topical Metformin shows potential for regenerating hair follicles and minimizing scarring in hair transplant donor areas, similar to Verteporfin but without its side effects. The discussion suggests considering Metformin for post-hair transplant care, though more human trials are needed.

Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

A 33-year-old female with androgenic alopecia experienced alopecia areata patches after PRP treatment. She is seeking others' experiences with PRP worsening alopecia areata.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

Treatments for hair loss, with the user considering Pyrilutamide and RU58841 as options. It is noted that although Pyrilutamide has been studied more and is allegedly more effective, there are doubts about its authenticity in the market. KX-826 is suggested as an alternative as it has a stronger effect than RU58841 and there is scientific research on it.

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

RU58841 from rudirect caused more hair shedding and itch, while anageninc's RU58841 improved the situation. Users are concerned about the quality and authenticity of RU58841 from different suppliers, including those from China.

A user shared their experience with a hair transplant, emphasizing the importance of avoiding caffeine 7 days before the procedure. Ignoring this advice led to reduced effectiveness of the numbing agent, causing significant discomfort during the transplant.

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.

The conversation discusses skepticism over the results of Pyrilutamide for hair regrowth, suggesting that results from rigorous trials are more trustworthy. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.